MRUS - Merus BV - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MRUS is currently covered by 10 analysts with an average price target of $97.42. This is a potential upside of $30.33 (45.21%) from yesterday's end of day stock price of $67.09.

Merus BV's activity chart (see below) currently has 86 price targets and 113 ratings on display. The stock rating distribution of MRUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 58.14% with an average time for these price targets to be met of 357.13 days.

Highest price target for MRUS is $111, Lowest price target is $70, average price target is $91.3.

Most recent stock forecast was given by AMI FADIA from NEEDHAM on 06-Aug-2025. First documented stock forecast 13-Jun-2016.

Currently out of the existing stock ratings of MRUS, 49 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$96

$32.61 (51.44%)

$88

7 days ago
(06-Aug-2025)

17/29 (58.62%)

$30.46 (46.48%)

353

Buy

$109

$45.61 (71.95%)

$109

4 months 16 days ago
(28-Mar-2025)

1/4 (25%)

$64.39 (144.34%)

650

Buy

$70

$6.61 (10.43%)

$76

5 months 3 days ago
(10-Mar-2025)

1/5 (20%)

$23.25 (49.73%)

375

Buy

$85

$21.61 (34.09%)

$85

5 months 10 days ago
(03-Mar-2025)

9/13 (69.23%)

$39.53 (86.94%)

344

Buy

$111

$47.61 (75.11%)

$93

10 months 12 days ago
(01-Oct-2024)

0/2 (0%)

$60.9 (121.56%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MRUS (Merus BV) average time for price targets to be met?

On average it took 357.13 days on average for the stock forecasts to be realized with a an average price target met ratio 58.14

Which analyst has the current highest performing score on MRUS (Merus BV) with a proven track record?

ETZER DAROUT

Which analyst has the most public recommendations on MRUS (Merus BV)?

Etzer Darout works at BMO and has 12 price targets and 8 ratings on MRUS

Which analyst is the currently most bullish on MRUS (Merus BV)?

Michael Schmitz with highest potential upside - $47.61

Which analyst is the currently most reserved on MRUS (Merus BV)?

David Nierengarten with lowest potential downside - -$22.11

Merus BV in the News

Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités

– Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 %et un taux de survie globale de 79 % à 12 mois – D’après le plan d’exploitation actuel de la société, la trésorerie et les...

Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung

– Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 %bei 43 auswertbaren Patienten und eine Gesamtüberlebensrate von 79 % nach 12 Monaten – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln und Barmitteläquivalenten, einschließlich des erfolgreichen Börsengangs mit einem Bruttoerlös von 345 Mio. USD,...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?